StockNews.com downgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) from a buy rating to a hold rating in a research report sent to investors on Monday morning.
Separately, TheStreet lowered Vanda Pharmaceuticals from a c- rating to a d rating in a research report on Thursday, February 8th.
View Our Latest Analysis on Vanda Pharmaceuticals
Vanda Pharmaceuticals Price Performance
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last announced its earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.05. Vanda Pharmaceuticals had a return on equity of 0.46% and a net margin of 1.30%. The firm had revenue of $45.27 million during the quarter, compared to analyst estimates of $37.00 million. As a group, equities analysts anticipate that Vanda Pharmaceuticals will post -0.06 EPS for the current fiscal year.
Institutional Investors Weigh In On Vanda Pharmaceuticals
Large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its holdings in Vanda Pharmaceuticals by 352.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 5,186 shares during the last quarter. CWM LLC increased its holdings in Vanda Pharmaceuticals by 61.1% in the 3rd quarter. CWM LLC now owns 7,205 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 2,732 shares during the last quarter. Raymond James & Associates purchased a new stake in Vanda Pharmaceuticals in the 4th quarter worth about $42,000. Mackenzie Financial Corp purchased a new stake in Vanda Pharmaceuticals in the 4th quarter worth about $46,000. Finally, Sherbrooke Park Advisers LLC purchased a new stake in Vanda Pharmaceuticals in the 3rd quarter worth about $52,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Featured Articles
- Five stocks we like better than Vanda Pharmaceuticals
- Stock Sentiment Analysis: How it Works
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- What is MarketRank™? How to Use it
- Merger or Not, Albertson’s Companies is a Good Buy
- Election Stocks: How Elections Affect the Stock Market
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.